New pump insulin could speed up blood sugar control for type 1 diabetes
NCT ID NCT06809621
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study tested a new fast-acting insulin called NNC0471-0119 in 43 adults with type 1 diabetes who use an insulin pump. The goal was to see how quickly the insulin enters the bloodstream, how long it works, and how safe it is compared to a standard insulin (insulin aspart). Each participant received both insulins at separate visits. The study lasted about 1-3 months and measured blood sugar-lowering effects and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0471-0119 (a fast-acting insulin)
What this could lead to
If successful, this could lead to a faster-acting insulin for insulin pumps, helping people with type 1 diabetes manage blood sugar more effectively after meals.
What could go wrong
This is a small, early-phase study (Phase 1) focused on safety and how the drug works in the body. It may not show better results than existing insulins, and further larger trials are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany